Diseases / Multiple System Atrophy
Multiple System Atrophy Clinical Trials
DiseaseMultiple system atrophy is a rare progressive neurodegenerative disorder characterized by autonomic failure plus parkinsonian and/or cerebellar motor features. Disease progression leads to increasing disability and reduced survival.
Continuously tracked·last revised
Data: CSV·JSON·Browse the trials
Follow Multiple System Atrophy
Email me when this page changes — new trials, changes of phase or status, and results as they are posted.
No mail is going out yet — your address is recorded now, used for nothing else, and never shared.
Thanks — your request is recorded. No mail is sent yet.
That did not work. Check the address and try again.
Recruiting Phase 3
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| MSA-01 in Multiple System Atrophy NCT07446894 | Phase 3 | Recruiting | Tokyo University | Started 2026-02 |
| An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy NCT07197866 | Phase 2 | Recruiting | Teva Branded Pharmaceutical Products R&D LLC | Started 2025-09 |
| A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) NCT06868628 | Phase 2 | Recruiting | Tiziana Life Sciences LTD | Started 2025-05 |
| A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy NCT06568237 | Phase 2 | Recruiting | Teva Branded Pharmaceutical Products R&D LLC | Started 2024-10 |
| The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism NCT06162013 | Phase 2 | Recruiting | Haukeland University Hospital | Started 2024-03 |
Recently started
Results recently posted
| Trial | Phase | Status | Sponsor | Results posted |
|---|---|---|---|---|
| Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients NCT04620382 | Early Phase 1 | Completed | Vanderbilt University Medical Center | Results posted 2026-08-07 |
| A Study of TAK-341 in Treatment of Multiple System Atrophy NCT05526391 | Phase 2 | Completed | Takeda | Results posted 2026-06-02 |
| Exenatide Once-weekly as a Treatment for Multiple System Atrophy NCT04431713 | Phase 2 | Completed | University College, London | Results posted 2025-06-27 |
| A Study of Lu AF82422 in Participants With Multiple System Atrophy NCT05104476 | Phase 2 | Active, not recruiting | H. Lundbeck A/S | Results posted 2024-12-27 |
| In-Home Care for Patients With PSP and Related Disorders NCT03552484 | Phase n/a | Completed | Rush University Medical Center | Results posted 2024-04-01 |
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Unknown | Available | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 7 | — | — | — | 3 | 1 | — | — | — | — | 11 |
| Phase 1 | 5 | 2 | — | 3 | 10 | 1 | 1 | — | — | — | 22 |
| Phase 1/2 | — | — | — | — | 1 | 1 | — | — | — | — | 2 |
| Phase 2 | 4 | 2 | — | 4 | 15 | 3 | 1 | 1 | — | — | 30 |
| Phase 2/3 | — | 1 | — | — | 1 | — | — | — | — | — | 2 |
| Phase 3 | 1 | 1 | — | 1 | 7 | 3 | — | — | — | — | 13 |
| Phase 4 | — | — | — | — | 2 | — | — | 1 | — | — | 3 |
| Not applicable | 13 | 1 | — | 1 | 23 | 1 | — | 10 | — | — | 49 |
| Unknown | 18 | 2 | 4 | 6 | 27 | 3 | 1 | 7 | 2 | 1 | 71 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Multiple System Atrophy | 11 | 22 | 2 | 30 | 2 | 13 | 3 | 49 | 71 | 203 |
| Parkinson Disease | 6 | 11 | 1 | 5 | — | 3 | 3 | 22 | 46 | 97 |
| Supranuclear Palsy, Progressive | — | — | — | 3 | — | 2 | 1 | 14 | 34 | 54 |
| Pure Autonomic Failure | 2 | 6 | 1 | 3 | — | 4 | 1 | 7 | 9 | 33 |
| Lewy Body Disease | 3 | 2 | — | — | — | — | 1 | 6 | 20 | 32 |
| Parkinsonian Disorders | — | — | — | — | — | 3 | 1 | 10 | 11 | 25 |
| Corticobasal Degeneration | — | — | — | 1 | — | — | — | 7 | 14 | 22 |
| Hypotension, Orthostatic | — | 4 | 1 | 2 | 1 | 3 | — | 6 | 1 | 18 |
| Neurodegenerative Diseases | — | 4 | — | 4 | — | 1 | — | 3 | 6 | 18 |
| Alzheimer Disease | — | 4 | — | — | — | — | — | 3 | 6 | 13 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Vanderbilt University | 9 | 0 |
| 2 | Vanderbilt University Medical Center | 9 | 0 |
| 3 | University Hospital, Bordeaux | 8 | 0 |
| 4 | University Hospital, Toulouse | 6 | 1 |
| 5 | MODAG GmbH | 5 | 0 |
| 6 | NYU Langone Health | 5 | 0 |
| 7 | Alterity Therapeutics | 4 | 0 |
| 8 | H. Lundbeck A/S | 4 | 1 |
| 9 | National Institute of Neurological Disorders and Stroke (NINDS) | 4 | 0 |
| 10 | Ruijin Hospital | 4 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Droxidopa | 8 |
| 2 | Midodrine | 5 |
| 3 | 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole | 4 |
| 4 | 8-hydroxyquinazolin-4(3H)-one | 3 |
| 5 | ATH434 | 3 |
| 6 | Blood Specimen Collection | 3 |
| 7 | Carbidopa | 3 |
| 8 | entacapone | 3 |
| 9 | Sugars | 3 |
| 10 | ampreloxetine | 2 |
Terminations
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05695378 Terminated | Terminated | Sponsor has decided to withdraw the study due to safety issue and re-initiate with a new clinical study | 2024-08-19 |
| NCT03901638 Terminated | Terminated | Project replanning | 2023-04-03 |
| NCT04020198 Terminated | Terminated | The assay under investigation did not show evidence of accurately detecting alpha-synuclein in specimens collected in the study other than CSF and the intention of the study was to identify less invasive ways to measure alpha-synuclein. | 2022-10-19 |
| NCT01119417 Withdrawn | Withdrawn | No participants were enrolled | 2021-05-31 |
| NCT03589976 Terminated | Terminated | Interim analysis showed early evidence of futility of sirolimus. Trial stopped per DSMB recommendation. | 2021-01-01 |
| NCT02149901 Terminated | Terminated | funding terminated | 2020-12-31 |
| NCT01292694 Terminated | Terminated | Could not enroll enough participants, and lost funding. | 2017-03-31 |
| NCT01607268 Terminated | Terminated | Could not enroll enough participants, and lost funding. | 2017-01-31 |
| NCT02445469 Terminated | Terminated | The results obtained are sufficient | 2016-12-31 |
| NCT00547911 Terminated | Terminated | Study terminated due to contamination droxidopa | 2013-04-30 |
Evidence
- Results reported
- 29.2%26 of 89 completed
- Published
- 15.7%14 of 89 completed
- Primary endpoint met
- 22.7%5 of 22 analyses
- Median months to report
- 12.5
Documents disclosed
Trial profile
- Median enrollment
- 66
- Median duration
- 40months
- Countries
- 38
- Study sites
- 1088
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 20
- Phase 1
- 26
- Phase 1/2
- 21
- Phase 2
- 50
- Phase 2/3
- 129
- Phase 3
- 181
- Phase 4
- 453
- Not applicable
- 42
- Unknown
- 190
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Nashville | United States | 37 |
| 2 | New York | United States | 26 |
| 3 | Boston | United States | 24 |
| 4 | Rochester | United States | 22 |
| 5 | Toulouse | France | 20 |
| 6 | Bordeaux | France | 18 |
| 7 | Boca Raton | United States | 14 |
| 8 | Dallas | United States | 14 |
| 9 | Beijing | China | 13 |
| 10 | Chicago | United States | 13 |